• AstraZeneca broadens its scope in blood cancers with $100M TeneoTwo buyout

    1 month ago - By MedCity News

    AstraZeneca is acquiring TeneoTwo in a $100 million bet on that biotech's lymphoma drug candidate, which is designed to go after two targets. It's the latest deal made by a big pharmaceutical company looking to get its hands on a new type of cancer therapy called a T cell engager.
    Read more ...